About Cellective Therapeutics
Cellective Therapeutics is a company based in Gaithersburg (United States) founded in 2003 was acquired by MedImmune in September 2005. Cellective Therapeutics has raised $27.5 million across 1 funding round from investors including Genentech, MedImmune and Intersouth Partners. Cellective Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Gaithersburg, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cellective Therapeutics
Cellective Therapeutics has successfully raised a total of $27.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $27.5 million completed in September 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellective Therapeutics
Cellective Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech, MedImmune and Intersouth Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life sciences and tech focused VC firm funding companies in the US
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm that does early stage investments in the US
|
Locked | Locked | Locked |
Investor details for Cellective Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellective Therapeutics
Investment portfolio details for Cellective Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellective Therapeutics
Detailed financials for Cellective Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellective Therapeutics Comparisons
Peer comparison for Cellective Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellective Therapeutics
Cellective Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Cellective Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellective Therapeutics
Complete news archive for Cellective Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellective Therapeutics
Cellective Therapeutics was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Cellective Therapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Cellective Therapeutics is a funded company, having raised a total of $27.5M across 1 funding round to date.
Cellective Therapeutics was established in 2003 in Gaithersburg, United States, as a biotech firm. Focus was placed on B cell research targeting cancer and autoimmune diseases. Three lead programs involving monoclonal antibodies against CD-19, CD-20, and CD-22 were developed. Acquisition by MedImmune occurred in October 2005, integrating the programs into AstraZenecas operations since 2007.
Cellective Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Cellective Therapeutics has 8 investors. Key investors include Genentech, MedImmune, Intersouth Partners, Alta Partners, and Forward Ventures.